FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309070530> ?p ?o ?g. }

• W4309070530 endingPage "441" @default.
• W4309070530 startingPage "435" @default.
• W4309070530 abstract "Romiplostim is a Food and Drug Administration (FDA)-approved therapy for immune thrombocytopenia (ITP). Biosimilar is a biological product that has no clinical meaningful difference from an existing FDA-approved reference product. It has a potential of lowering health-care-related cost. Biosimilar of romiplostim can be made available to patients with ITP at a low cost and can be beneficial in providing the best therapy. Thus, the efficacy and safety of biosimilar romiplostim (ENZ110) was compared with innovator romiplostim (Nplate) with respect to platelet response in patients with chronic ITP. This was a prospective, multicenter, randomized, and double-blind clinical trial. Patients with chronic ITP, aged 18-65 years, were enrolled in a study and were randomized to receive either ENZ110 or Nplate in a 3:1 ratio for a treatment period of 12 weeks, respectively. After completion of the treatment period, the patients were followed-up for one week to evaluate the platelet response and to monitor the adverse events (AEs). Over the duration of 12 weeks, platelet response of > 50 × 109/L was achieved in 85.3% patients treated with ENZ110 and in 75.0% patients treated with Nplate in per protocol population. In intent-to-treat population, 83.8% patients with ENZ110 and 76.9% patients with Nplate achieved a platelet response of > 50 × 109/L. In the ENZ110 group, 111 AEs were recorded in 66.7% patients, while 18 AEs were reported in 61.5% patients in the Nplate group. The study demonstrated non-inferiority with comparable efficacy and safety between biosimilar romiplostim and innovator romiplostim in patients with chronic ITP. Trial registration number and date of registration: CTRI/2019/04/018614." @default.
• W4309070530 created "2022-11-21" @default.
• W4309070530 creator A5021708672 @default.
• W4309070530 creator A5027123388 @default.
• W4309070530 creator A5028467126 @default.
• W4309070530 creator A5028946052 @default.
• W4309070530 creator A5032256244 @default.
• W4309070530 creator A5033930354 @default.
• W4309070530 creator A5041746884 @default.
• W4309070530 creator A5050618790 @default.
• W4309070530 creator A5060132891 @default.
• W4309070530 creator A5062777468 @default.
• W4309070530 creator A5066787650 @default.
• W4309070530 creator A5079868316 @default.
• W4309070530 creator A5085804580 @default.
• W4309070530 creator A5085889753 @default.
• W4309070530 creator A5086544854 @default.
• W4309070530 creator A5087630623 @default.
• W4309070530 date "2022-11-15" @default.
• W4309070530 modified "2023-09-30" @default.
• W4309070530 title "Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia" @default.
• W4309070530 cites W1969903307 @default.
• W4309070530 cites W1980002878 @default.
• W4309070530 cites W1991617987 @default.
• W4309070530 cites W1993960588 @default.
• W4309070530 cites W2017955228 @default.
• W4309070530 cites W2057964077 @default.
• W4309070530 cites W2086899194 @default.
• W4309070530 cites W2139745353 @default.
• W4309070530 cites W2167810526 @default.
• W4309070530 cites W2352796693 @default.
• W4309070530 cites W2911447041 @default.
• W4309070530 cites W2915557171 @default.
• W4309070530 cites W4211167997 @default.
• W4309070530 cites W4211212002 @default.
• W4309070530 cites W4244215862 @default.
• W4309070530 doi "https://doi.org/10.1007/s12288-022-01602-5" @default.
• W4309070530 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37304488" @default.
• W4309070530 hasPublicationYear "2022" @default.
• W4309070530 type Work @default.
• W4309070530 citedByCount "0" @default.
• W4309070530 crossrefType "journal-article" @default.
• W4309070530 hasAuthorship W4309070530A5021708672 @default.
• W4309070530 hasAuthorship W4309070530A5027123388 @default.
• W4309070530 hasAuthorship W4309070530A5028467126 @default.
• W4309070530 hasAuthorship W4309070530A5028946052 @default.
• W4309070530 hasAuthorship W4309070530A5032256244 @default.
• W4309070530 hasAuthorship W4309070530A5033930354 @default.
• W4309070530 hasAuthorship W4309070530A5041746884 @default.
• W4309070530 hasAuthorship W4309070530A5050618790 @default.
• W4309070530 hasAuthorship W4309070530A5060132891 @default.
• W4309070530 hasAuthorship W4309070530A5062777468 @default.
• W4309070530 hasAuthorship W4309070530A5066787650 @default.
• W4309070530 hasAuthorship W4309070530A5079868316 @default.
• W4309070530 hasAuthorship W4309070530A5085804580 @default.
• W4309070530 hasAuthorship W4309070530A5085889753 @default.
• W4309070530 hasAuthorship W4309070530A5086544854 @default.
• W4309070530 hasAuthorship W4309070530A5087630623 @default.
• W4309070530 hasBestOaLocation W43090705301 @default.
• W4309070530 hasConcept C109159458 @default.
• W4309070530 hasConcept C126322002 @default.
• W4309070530 hasConcept C168563851 @default.
• W4309070530 hasConcept C197934379 @default.
• W4309070530 hasConcept C203092338 @default.
• W4309070530 hasConcept C2776915898 @default.
• W4309070530 hasConcept C2777863708 @default.
• W4309070530 hasConcept C28328180 @default.
• W4309070530 hasConcept C2908647359 @default.
• W4309070530 hasConcept C535046627 @default.
• W4309070530 hasConcept C54355233 @default.
• W4309070530 hasConcept C59491497 @default.
• W4309070530 hasConcept C71924100 @default.
• W4309070530 hasConcept C86803240 @default.
• W4309070530 hasConcept C99454951 @default.
• W4309070530 hasConceptScore W4309070530C109159458 @default.
• W4309070530 hasConceptScore W4309070530C126322002 @default.
• W4309070530 hasConceptScore W4309070530C168563851 @default.
• W4309070530 hasConceptScore W4309070530C197934379 @default.
• W4309070530 hasConceptScore W4309070530C203092338 @default.
• W4309070530 hasConceptScore W4309070530C2776915898 @default.
• W4309070530 hasConceptScore W4309070530C2777863708 @default.
• W4309070530 hasConceptScore W4309070530C28328180 @default.
• W4309070530 hasConceptScore W4309070530C2908647359 @default.
• W4309070530 hasConceptScore W4309070530C535046627 @default.
• W4309070530 hasConceptScore W4309070530C54355233 @default.
• W4309070530 hasConceptScore W4309070530C59491497 @default.
• W4309070530 hasConceptScore W4309070530C71924100 @default.
• W4309070530 hasConceptScore W4309070530C86803240 @default.
• W4309070530 hasConceptScore W4309070530C99454951 @default.
• W4309070530 hasIssue "3" @default.
• W4309070530 hasLocation W43090705301 @default.
• W4309070530 hasLocation W43090705302 @default.
• W4309070530 hasLocation W43090705303 @default.
• W4309070530 hasOpenAccess W4309070530 @default.
• W4309070530 hasPrimaryLocation W43090705301 @default.
• W4309070530 hasRelatedWork W2015608900 @default.
• W4309070530 hasRelatedWork W2066017887 @default.
• W4309070530 hasRelatedWork W3154723227 @default.

• next